Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs

This is a summary. Read the complete story at Yahoo Finance below.

Related Stories

marketsabout 1 hour ago

A 10% risk-free yield? For some, yes.

This could be a bargain, especially for very high earners and those in high-tax locations.

MarketWatch

marketsabout 2 hours ago

This is why you might see 8% mortgage rates soon

Also in Weekend Reads: The bond market selloff’s consequences for AI, a threat to the buy-and-hold investment style and advice from the Moneyist.

MarketWatch

marketsabout 2 hours ago

Choosing these AI-exposed college majors could dent your job prospects — and lower your pay

At a time when many college students say they are rethinking their academic focus because of AI, new findings supply hard data on the potential costs of these decisions.

MarketWatch